Market PotentialPerinatal depression is under-diagnosed and under-treated, which may lead to adverse outcomes for the mother and the child, indicating a significant market need for effective treatments like LPCN 1154.
Product DevelopmentLPCN 1154, Lipocine’s oral formulation of brexanolone, further improves the efficacy and safety profile compared to zuranolone, with rapid onset of action and a treatment duration of 48 hours.